D
Darren J. Burgess
Researcher at Institute of Cancer Research
Publications - 336
Citations - 2533
Darren J. Burgess is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Gene expression & Regulation of gene expression. The author has an hindex of 17, co-authored 325 publications receiving 2262 citations. Previous affiliations of Darren J. Burgess include Watson School of Biological Sciences & Cold Spring Harbor Laboratory.
Papers
More filters
Journal ArticleDOI
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess,Jason Doles,Lars Zender,Wen Xue,Beicong Ma,Beicong Ma,W. Richard McCombie,Gregory J. Hannon,Gregory J. Hannon,Scott W. Lowe,Scott W. Lowe,Michael T. Hemann,Michael T. Hemann +12 more
TL;DR: Results highlight the utility of pooled shRNA screens for identifying genetic determinants of chemotherapy response and suggest strategies for improving the effectiveness of topoisomerase poisons in the clinic.
Journal ArticleDOI
Suppression of tumorigenesis by the p53 target PUMA.
Michael T. Hemann,Jack T. Zilfou,Zhen Zhao,Darren J. Burgess,Gregory J. Hannon,Scott W. Lowe +5 more
TL;DR: Stable RNA interference is used to examine the role of PUMA, a p53 target gene and proapoptotic member of the Bcl2 family, in p53-mediated tumor suppression and demonstrates the utility of RNA interference for evaluating putative tumor suppressor genes in vivo.
Journal ArticleDOI
Spatial transcriptomics coming of age.
TL;DR: Two new spatial transcriptomics techniques published in Nature and Science bring an important step closer to the goal of achieving transcriptome-wide data at single-cell resolution.
Journal ArticleDOI
DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
Sarah A. Martin,Nuala McCabe,Michelle J Mullarkey,Robert Cummins,Darren J. Burgess,Yusaku Nakabeppu,Sugako Oka,Elaine W. Kay,Christopher J. Lord,Alan Ashworth +9 more
TL;DR: Synthetic sickness/lethality can be exploited to develop therapeutic strategies for cancer and deficiency in MSH2 is SSL with inhibition of the DNA polymerase POLB, whereas deficiency in MLH1 isSSL with DNA polymerases POLG inhibition.
Journal ArticleDOI
Tissue-specific and reversible RNA interference in transgenic mice
Ross A. Dickins,Katherine McJunkin,Katherine McJunkin,Eva Hernando,Prem K. Premsrirut,Valery Krizhanovsky,Darren J. Burgess,Darren J. Burgess,Sang Yong Kim,Carlos Cordon-Cardo,Lars Zender,Gregory J. Hannon,Gregory J. Hannon,Gregory J. Hannon,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe +16 more
TL;DR: A simple transgenic system to reversibly control endogenous gene expression using RNA interference (RNAi) in mice by adapting the tetracycline (tet)-responsive system previously used for gene overexpression, with potential broad application in basic biology and drug target validation.